• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

F2 Gene Record

  • Summary
  • Interactions
  • Claims
  • F2 2147 Druggable Genome

    Alternate Names:

    2147
    COAGULATION FACTOR II, THROMBIN
    F2
    PT
    RPRGL2
    THPH1
    176930
    3535
    ENSG00000180210
    OTTHUMG00000150344
    Activation peptide fragment 1
    Prothrombin
    Activation peptide fragment 2
    Thrombin light chain
    Thrombin heavy chain
    Coagulation factor II
    P00734
    THRB_HUMAN
    PROTHROMBIN PRECURSOR (EC 3.4.21.5) (COAGULATION FACTOR II). [SOURCE:UNIPROT/SWISSPROT;ACC:P00734]
    PA157
    Coagulation factor IIa
    T94033

    Gene Info:

    Interpro Acc IPR001254
    Human Readable Name DRUGGABLE GENOME
    Uniprot Evidence 1: Evidence at protein level
    Interpro Short Name Peptidase_S1_S6
    Interpro Name Peptidase S1/S6, chymotrypsin/Hap
    Interpro Type Domain
    Uniprot Status Swiss-Prot
    Human Readable Name PROTEASE
    Target Class Enzymes
    Target Subclass EC:3.4.21.5
    Target Subclass 3.4.21.5
    Target Main Class Enzymes
    Gene Biotype PROTEIN_CODING
    (9 More Sources)

    Gene Categories: Category Details

    GROWTH FACTOR
    PROTEASE
    EXTERNAL SIDE OF PLASMA MEMBRANE
    DRUGGABLE GENOME

    Publications:

    Eriksson, 2000, New therapeutic options in deep vein thrombosis prophylaxis., Semin. Hematol.
    Turpie, 1999, Anticoagulants in acute coronary syndromes., Am. J. Cardiol.
    Fabrizio, 2001, Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass., J Extra Corpor Technol
    Szaba et al., 2002, Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo., Blood
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Warkentin, 2000, Venous thromboembolism in heparin-induced thrombocytopenia., Curr Opin Pulm Med
    Serebruany et al., 1998, A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study., J. Thromb. Thrombolysis
    Sakai et al., 1999, Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model., Cardiovasc Surg
    Jang et al., 1999, A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study., J. Am. Coll. Cardiol.
    Matsuo et al., 1995, Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: A Multicenter Clinical Trial of Argatroban., J. Thromb. Thrombolysis
    Kawada et al., 1999, Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture., Jpn. J. Thorac. Cardiovasc. Surg.
    Gladwell, 2002, Bivalirudin: a direct thrombin inhibitor., Clin Ther
    Carswell et al., 2002, Bivalirudin: a review of its potential place in the management of acute coronary syndromes., Drugs
    Kleiman et al., 2002, Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide., Am. Heart J.
    Bates, 2001, Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes., Curr Cardiol Rep
    Scatena, 2000, Bivalirudin: a new generation antithrombotic drug., Expert Opin Investig Drugs
    Testa et al., 2007, The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile., Expert Opin Drug Saf
    Ersdal et al., 2005, No influence of food on the pharmacokinetics, pharmacodynamics or tolerability of the 24mg and 36mg oral tablet formulations of ximelagatran., Clin Drug Investig
    Bergqvist et al., 2004, Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran : a multicentre study of thromboprophylaxis in elective abdominal surgery., Clin Drug Investig
    Ho et al., 2006, Ximelagatran: direct thrombin inhibitor., Vasc Health Risk Manag
    McCarthy et al., 1989, Retinoid-induced hemorrhaging and bone toxicity in rats fed diets deficient in vitamin K., Toxicol. Appl. Pharmacol.
    Casper et al., 1989, Evaluation of vitamin K3 feed additive for prevention of sweet clover disease., J. Vet. Diagn. Invest.
    Lee et al., 1999, Advantages of calcium green-1 over other fluorescent dyes in measuring cytosolic calcium in platelets., Anal. Biochem.
    Wang et al., 1995, The growth inhibitory effects of vitamins K and their actions on gene expression., Hepatology
    Szejtli et al., 1983, Preparation, properties and biological activity of beta-cyclodextrin inclusion complex of menadione., Pharmazie
    Blackburn C et al., 2010, Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome., Bioorg Med Chem Lett
    Luesch H et al., 2000, Apramides A-G, novel lipopeptides from the marine cyanobacterium Lyngbya majuscula., J Nat Prod
  • BIVALIRUDIN   F2

    Interaction Score: 21.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name bivalirudin,Angiomax, Angiox
    Novel drug target Established target
    Mechanism of Interaction Thrombin inhibitor

    PMIDs:
    11833835 11929334 11752352 11923794 11504570 11060732


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • XIMELAGATRAN   F2

    Interaction Score: 14.92

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17688383 17532684 17516699 11752352 17319469


    Sources:
    TdgClinicalTrial TEND

  • ARGATROBAN   F2

    Interaction Score: 9.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Argatroban
    Mechanism of Interaction Thrombin inhibitor

    PMIDs:
    10608050 10353669 10362188 11752352 10608016 10226408


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • LEPIRUDIN   F2

    Interaction Score: 7.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name lepirudin (rDNA) for injection,Refludan
    Novel drug target Established target
    Direct Interaction yes

    PMIDs:
    11055889 10505536 11467439 11807012 11752352 10912644


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • APRAMIDE A   F2

    Interaction Score: 4.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10978206


    Sources:
    DTC

  • ODIPARCIL   F2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CHEMBL1083499   F2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CYANIN   F2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DABIGATRAN ETEXILATE MESYLATE   F2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Thrombin inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PEGMUSIRUDIN   F2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CHEMBL586628   F2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DESIRUDIN   F2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Thrombin inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CYANIDIN   F2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ATECEGATRAN METOXIL   F2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name AZD-0837

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • AZD-8165   F2

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DABIGATRAN   F2

    Interaction Score: 0.95

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Dabigatran
    Novel drug target Established target
    Mechanism of Interaction Thrombin inhibitor

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • LUSUTROMBOPAG   F2

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • ENOXAPARIN   F2

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Lovenox
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • AVATROMBOPAG   F2

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • MENADIONE   F2

    Interaction Score: 0.46

    Interaction Types & Directionality:
    activator (activating)

    Interaction Info:

    PMIDs:
    2922761 2484931 10469489 7657295 6867080


    Sources:
    TEND

  • MELAGATRAN   F2

    Interaction Score: 0.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ANISINDIONE   F2

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CIANIDANOL   F2

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • (-)-EPICATECHIN   F2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SILIBININ   F2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • HEPARIN   F2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name octaparine, AVE-5026
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND

  • TAMOXIFEN   F2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • BORTEZOMIB   F2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20875739


    Sources:
    DTC

  • QUERCETIN   F2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Ensembl: ENSG00000180210

    • Version: 101_38

    Alternate Names:
    F2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • HopkinsGroom: P00734

    • Version: 11-September-2012

    Alternate Names:
    THRB_HUMAN Uniprot Id
    PROTHROMBIN Uniprot Protein Name
    P00734 Uniprot Accession

    Gene Info:
    Interpro Acc IPR001254
    Human Readable Name DRUGGABLE GENOME
    Uniprot Evidence 1: Evidence at protein level

    Gene Categories:
    PROTEASE, DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000180210

    • Version: 26-July-2011

    Alternate Names:
    PROTHROMBIN PRECURSOR (EC 3.4.21.5) (COAGULATION FACTOR II). [SOURCE:UNIPROT/SWISSPROT;ACC:P00734] Description
    F2 Display Id
    ENSG00000180210 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TdgClinicalTrial: P00734

    • Version: January-2014

    Alternate Names:
    F2 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:3.4.21.5

    Publications:

  • TEND: P00734

    • Version: 01-August-2011

    Alternate Names:
    2147 Entrez Gene Id
    F2 Gene Symbol
    ENSG00000180210 Ensembl Gene Id

    Gene Info:
    Target Subclass 3.4.21.5
    Target Main Class Enzymes

    Publications:

  • PharmGKB: F2

    • Version: 18-August-2020

    Alternate Names:
    PA157 PharmGKB ID

    Gene Info:

    Publications:
    Sidney S et al., 2004, Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives., Contraception
    McDaid A et al., 2017, Risk prediction of developing venous thrombosis in combined oral contraceptive users., PLoS One
    Legnani C et al., 2002, Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use., Eur Heart J

  • TTD: Coagulation factor IIa

    • Version: 2020.06.01

    Alternate Names:
    F2 TTD Gene Abbreviation
    T94033 TTD Target ID

    Gene Info:

    Publications:
    Salas CM et al., 2013, Antithrombin III Utilization in a Large Teaching Hospital., P T
    Ni X et al., 2011, Nucleic acid aptamers: clinical applications and promising new horizons., Curr Med Chem

  • DTC: F2

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Luesch H et al., 2000, Apramides A-G, novel lipopeptides from the marine cyanobacterium Lyngbya majuscula., J Nat Prod
    Blackburn C et al., 2010, Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome., Bioorg Med Chem Lett

  • ChemblInteractions: F2

    • Version: chembl_23

    Alternate Names:
    F2 GENE_SYMBOL
    Prothrombin UNIPROT
    Activation peptide fragment 1 UNIPROT

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000180210

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000180210 Gene Symbol
    F2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • dGene: F2

    • Version: 27-Jun-2013

    Alternate Names:
    2147 Gene ID
    PT dGene Synonym
    RPRGL2 dGene Synonym

    Gene Info:

    Gene Categories:
    PROTEASE

    Publications:

  • GO: F2

    • Version: 01-February-2022

    Alternate Names:

    Gene Info:

    Gene Categories:
    GROWTH FACTOR, EXTERNAL SIDE OF PLASMA MEMBRANE

    Publications:

  • FDA: F2

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21